323 related articles for article (PubMed ID: 20080770)
1. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses.
Kiso M; Takahashi K; Sakai-Tagawa Y; Shinya K; Sakabe S; Le QM; Ozawa M; Furuta Y; Kawaoka Y
Proc Natl Acad Sci U S A; 2010 Jan; 107(2):882-7. PubMed ID: 20080770
[TBL] [Abstract][Full Text] [Related]
2. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
Sleeman K; Mishin VP; Deyde VM; Furuta Y; Klimov AI; Gubareva LV
Antimicrob Agents Chemother; 2010 Jun; 54(6):2517-24. PubMed ID: 20350949
[TBL] [Abstract][Full Text] [Related]
3. [Susceptibility of pandemic influenza virus A 2009 H1N1 and highly pathogenic avian influenza virus A H5N1 to antiinfluenza agents in cell culture].
Fediakina IT; Shchelkanov MIu; Deriabin PG; Leneva IA; Gudova NV; Kondrat'eva TV; L'vov DK
Antibiot Khimioter; 2011; 56(3-4):3-9. PubMed ID: 21913403
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.
Tarbet EB; Vollmer AH; Hurst BL; Barnard DL; Furuta Y; Smee DF
Arch Virol; 2014 Jun; 159(6):1279-91. PubMed ID: 24311151
[TBL] [Abstract][Full Text] [Related]
5. Favipiravir (T-705), a novel viral RNA polymerase inhibitor.
Furuta Y; Gowen BB; Takahashi K; Shiraki K; Smee DF; Barnard DL
Antiviral Res; 2013 Nov; 100(2):446-54. PubMed ID: 24084488
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses.
Kiso M; Kubo S; Ozawa M; Le QM; Nidom CA; Yamashita M; Kawaoka Y
PLoS Pathog; 2010 Feb; 6(2):e1000786. PubMed ID: 20195462
[TBL] [Abstract][Full Text] [Related]
7. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice.
Smee DF; Hurst BL; Wong MH; Bailey KW; Tarbet EB; Morrey JD; Furuta Y
Antimicrob Agents Chemother; 2010 Jan; 54(1):126-33. PubMed ID: 19901093
[TBL] [Abstract][Full Text] [Related]
8. Oseltamivir resistance among influenza viruses: surveillance in northern Viet Nam, 2009-2012.
Hoang Vu MP; Nguyen CT; Nguyen le KH; Nguyen TK; Le QM
Western Pac Surveill Response J; 2013; 4(2):25-9. PubMed ID: 24015368
[TBL] [Abstract][Full Text] [Related]
9. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses.
Leneva IA; Roberts N; Govorkova EA; Goloubeva OG; Webster RG
Antiviral Res; 2000 Nov; 48(2):101-15. PubMed ID: 11114412
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model.
Govorkova EA; Ilyushina NA; McClaren JL; Naipospos TS; Douangngeun B; Webster RG
Antimicrob Agents Chemother; 2009 Jul; 53(7):3088-96. PubMed ID: 19349520
[TBL] [Abstract][Full Text] [Related]
11. Neuraminidase amino acids 149 and 347 determine the infectivity and oseltamivir sensitivity of pandemic influenza A/H1N1 (2009) and avian influenza A/H5N1.
Yongkiettrakul S; Nivitchanyong T; Pannengpetch S; Wanitchang A; Jongkaewwattana A; Srimanote P
Virus Res; 2013 Aug; 175(2):128-33. PubMed ID: 23639424
[TBL] [Abstract][Full Text] [Related]
12. Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice.
Park S; Kim JI; Lee I; Lee S; Hwang MW; Bae JY; Heo J; Kim D; Jang SI; Kim H; Cheong HJ; Song JW; Song KJ; Baek LJ; Park MS
PLoS One; 2014; 9(7):e101325. PubMed ID: 24992479
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
Sidwell RW; Barnard DL; Day CW; Smee DF; Bailey KW; Wong MH; Morrey JD; Furuta Y
Antimicrob Agents Chemother; 2007 Mar; 51(3):845-51. PubMed ID: 17194832
[TBL] [Abstract][Full Text] [Related]
14. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice.
Smee DF; Hurst BL; Wong MH; Bailey KW; Morrey JD
Antimicrob Agents Chemother; 2009 May; 53(5):2120-8. PubMed ID: 19273672
[TBL] [Abstract][Full Text] [Related]
15. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro.
Nguyen JT; Hoopes JD; Le MH; Smee DF; Patick AK; Faix DJ; Blair PJ; de Jong MD; Prichard MN; Went GT
PLoS One; 2010 Feb; 5(2):e9332. PubMed ID: 20179772
[TBL] [Abstract][Full Text] [Related]
16. Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus.
Baz M; Carbonneau J; Rhéaume C; Cavanagh MH; Boivin G
Viruses; 2018 Nov; 10(11):. PubMed ID: 30400276
[TBL] [Abstract][Full Text] [Related]
17. Influenza viruses resistant to neuraminidase inhibitors.
Nitsch-Osuch A; Brydak LB
Acta Biochim Pol; 2014; 61(3):505-8. PubMed ID: 25195142
[TBL] [Abstract][Full Text] [Related]
18. Human-like receptor specificity does not affect the neuraminidase-inhibitor susceptibility of H5N1 influenza viruses.
Ilyushina NA; Govorkova EA; Gray TE; Bovin NV; Webster RG
PLoS Pathog; 2008 Apr; 4(4):e1000043. PubMed ID: 18404209
[TBL] [Abstract][Full Text] [Related]
19. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro.
Nguyen JT; Hoopes JD; Smee DF; Prichard MN; Driebe EM; Engelthaler DM; Le MH; Keim PS; Spence RP; Went GT
Antimicrob Agents Chemother; 2009 Oct; 53(10):4115-26. PubMed ID: 19620324
[TBL] [Abstract][Full Text] [Related]
20. Influenza A H5N1 clade 2.3.4 virus with a different antiviral susceptibility profile replaced clade 1 virus in humans in northern Vietnam.
Le MT; Wertheim HF; Nguyen HD; Taylor W; Hoang PV; Vuong CD; Nguyen HL; Nguyen HH; Nguyen TQ; Nguyen TV; Van TD; Ngoc BT; Bui TN; Nguyen BG; Nguyen LT; Luong ST; Phan PH; Pham HV; Nguyen T; Fox A; Nguyen CV; Do HQ; Crusat M; Farrar J; Nguyen HT; de Jong MD; Horby P
PLoS One; 2008 Oct; 3(10):e3339. PubMed ID: 18836532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
